Marc Labriffe

ORCID: 0000-0001-5840-8904
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Renal Transplantation Outcomes and Treatments
  • Antibiotics Pharmacokinetics and Efficacy
  • Pharmacological Effects and Toxicity Studies
  • Cytomegalovirus and herpesvirus research
  • Antimicrobial Resistance in Staphylococcus
  • Herpesvirus Infections and Treatments
  • Transplantation: Methods and Outcomes
  • Organ Transplantation Techniques and Outcomes
  • Statistical Methods in Clinical Trials
  • HIV/AIDS drug development and treatment
  • Venous Thromboembolism Diagnosis and Management
  • Vascular anomalies and interventions
  • Diagnosis and Treatment of Venous Diseases
  • Pregnancy and Medication Impact
  • Bacterial Identification and Susceptibility Testing
  • HIV Research and Treatment
  • Diabetes Treatment and Management
  • Analytical Chemistry and Chromatography
  • Colorectal Cancer Screening and Detection
  • Colorectal and Anal Carcinomas
  • Clinical Reasoning and Diagnostic Skills
  • Cerebral Venous Sinus Thrombosis
  • Colorectal Cancer Surgical Treatments
  • Oropharyngeal Anatomy and Pathologies
  • Neonatal and Maternal Infections

Université de Limoges
2020-2025

Inserm
2020-2025

Centre Hospitalier Universitaire de Limoges
2020-2025

Hôpital Dupuytren
2020-2024

Fédération Hospitalo-Universitaire, Paris Center for Microbiome Medicine
2024

Centre Hospitalier Universitaire d'Angers
2014-2023

Université d'Angers
2023

Hôpital Universitaire Dupuytren
2022-2023

The aim of this work is to estimate the area‐under blood concentration curve tacrolimus (TAC) following b.i.d. or q.d. dosing in organ transplant patients, using Xgboost machine learning (ML) models. A total 4,997 and 1,452 TAC interdose area under curves (AUCs) from patients on TAC, sent our Immunosuppressant Bayesian Dose Adjustment expert system ( www.pharmaco.chu‐limoges.fr/ ) for AUC estimation dose recommendation based concentrations measured at least 3 sampling times (predose, ~ 1...

10.1002/cpt.2123 article EN Clinical Pharmacology & Therapeutics 2020-11-30

ABSTRACT Daptomycin is a concentration-dependent lipopeptide antibiotic for which exposure/effect relationships have been shown. Machine learning (ML) algorithms, developed to predict the individual exposure drugs, shown very good performances in comparison maximum posteriori Bayesian estimation (MAP-BE). The aim of this work was area under blood concentration curve (AUC) daptomycin from two samples and few covariates using XGBoost ML algorithm trained on Monte Carlo simulations. Five...

10.1128/aac.01415-23 article EN Antimicrobial Agents and Chemotherapy 2024-03-19

Therapeutic drug monitoring of mycophenolic acid (MPA) based on area under the curve (AUC) is well‐established and machine learning (ML) approaches could help to estimate AUC. The aim this work AUC MPA in organ transplant patients using extreme gradient boosting (Xgboost R package) ML models. A total 12,877 from 0 12 hours (AUC 0–12 h ) requests 6,884 sent our Immunosuppressant Bayesian Dose Adjustment expert system ( https://abis.chu‐limoges.fr for estimation dose recommendation...

10.1002/cpt.2216 article EN Clinical Pharmacology & Therapeutics 2021-02-24

Abstract Introduction Valganciclovir, a prodrug of ganciclovir (GCV), is used to prevent cytomegalovirus infection after transplantation, with doses adjusted based on creatinine clearance (CrCL) target GCV AUC0-24 h 40–60 mg*h/L. This sometimes leads overexposure or underexposure. study aimed train, test and validate machine learning (ML) algorithms for accurate estimation in solid organ transplantation. Methods We simulated patients different dosing regimen (900 mg/24 h, 450 mg/48 mg/72 h)...

10.1208/s12248-025-01034-9 article EN cc-by The AAPS Journal 2025-02-28

Interpretation of kidney graft biopsies using the Banff classification is still heterogeneous. In this study, extreme gradient boosting classifiers learned from two large training datasets (n = 631 and 304 cases) where "reference diagnoses" were not strictly defined following rules but central reading by expert pathologists further interpreted consensually experienced transplant nephrologists, in light clinical context. three external validation 3744, 589, 360), yielded a mean ROC curve AUC...

10.1111/ajt.17192 article EN cc-by-nc-nd American Journal of Transplantation 2022-09-05

Tacrolimus is an immunosuppressant largely used in heart transplantation. However, the calculation of its exposure based on area under curve (AUC) requires use a population pharmacokinetic (PK) model. The aims this work were (i) to develop PK model for tacrolimus transplant patients, (ii) derive maximum posteriori Bayesian estimator (MAP-BE) limited sampling strategy (LSS) and (iii) estimate probabilities target attainment (PTAs) AUC trough concentration (C0).

10.1111/bcp.15857 article EN British Journal of Clinical Pharmacology 2023-07-21

The aim of this work was to evaluate, in a large data set renal transplant recipients, the intraindividual variability area under curve (AUC)/predose concentration (C0) ratio comparison with that AUC, C0, AUC/dose, and C0/dose.Patients at least 2 tacrolimus AUC estimation requests were extracted from Immunosuppressant Bayesian dose Adjustment website, relative variations between consecutive visits for different metrics calculated compared.Data 1325 patients on (3827 measured C0 estimated...

10.1097/tp.0000000000004405 article EN Transplantation 2022-11-02

Intravenous ganciclovir and oral valganciclovir display significant variability in pharmacokinetics, particularly children. Therapeutic drug monitoring currently relies on the area under concentration-time (AUC). Machine-learning (ML) algorithms represent an interesting alternative to Maximum-a-Posteriori Bayesian-estimators for AUC estimation. The goal of our study was develop validate ML-based limited sampling strategy (LSS) approach determine

10.1128/aac.00860-24 article EN Antimicrobial Agents and Chemotherapy 2024-08-28

The clinical impact of individual dose adjustment mycophenolate mofetil is still debated, due to conflicting results from randomized trials. This retrospective study aimed compare 3-year rejection-free survival and adverse effects between adult kidney transplant recipients (KTRs) with or without model-informed precision dosing (MIPD). MIPD defined here as mycophenolic acid area under the curve (AUC

10.1002/cpt.3206 article EN cc-by-nc Clinical Pharmacology & Therapeutics 2024-02-19

Aims Intravenous mycophenolate mofetil (IV MMF), a prodrug of mycophenolic acid (MPA), is used during nonmyeloablative and reduced‐intensity conditioning haematopoetic stem cell transplantation (HCT) to improve engraftment reduce graft‐versus‐host disease. The aims this study were develop population pharmacokinetic models Bayesian estimators based on limited sampling strategies allow for individual dose adjustment intravenous administered by infusion in haematopoietic transplant patients....

10.1111/bcp.14261 article EN British Journal of Clinical Pharmacology 2020-02-19

Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and dose-limiting adverse side effect of treatment. CIPN affects the oncological prognosis patients, as well their quality life. To date, no specific pharmacological therapy has demonstrated effectiveness in preventing CIPN. Accumulating preclinical evidence suggests that renin-angiotensin system (RAS) inhibitors may have neuroprotective effects. One hundred twenty patients were included this observational study followed from...

10.3390/jcm11102939 article EN Journal of Clinical Medicine 2022-05-23

Background: The Immunosuppressant Bayesian Dose Adjustment web site aids clinicians and pharmacologists involved in the care of transplant recipients; it proposes dose adjustments based on estimated area under concentration–time curve (AUCs). Three concentrations (T 20 min , T 1 h 3 ) are sufficient to estimate mycophenolic acid (MPA) AUC 0–12 pediatric kidney recipients. This study investigates mycophenolate mofetil (MMF) doses MPA values recipients, target exposure attainment when proposed...

10.1097/ftd.0000000000001087 article EN Therapeutic Drug Monitoring 2023-02-22
Coming Soon ...